Value proposition

A clinical-stage biotech company that aims to develop the world’s most potent vaccines for cancer and infectious disease

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease.

With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

oncology, cancer vaccines, personalized medicine, COVID-19, HIV, artificial intelligence, machine learning, deep learning, epitope discovery, T cells, personalized cancer vaccine, off-the-shelf cancer vaccine, individualized vaccine, colorectal cancer, CRC, MSS-CRC, immunology, translational medicine, drug development, biotechnology, and infectious disease